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One sentence summary: Degradation of tissue debris and recovery from neuroinflammatory 21 
disease are impaired in Atg7-deficient microglia, a process mirrored by aging. 22 
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Abstract  23 
Multiple Sclerosis (MS) is a leading cause of incurable progressive disability in young adults 24 
caused by inflammation and neurodegeneration in the central nervous system (CNS). The capacity 25 
of microglia to clear tissue debris is essential for maintaining and restoring CNS homeostasis. This 26 
capacity diminishes with age, and age strongly associates with MS disease progression, although 27 
the underlying mechanisms are still largely elusive. Herein, we demonstrate that the recovery from 28 
CNS inflammation in a murine model of MS is dependent on the ability of microglia to clear tissue 29 
debris. Microglia-specific deletion of the autophagy regulator Atg7, but not the canonical 30 
macroautophagy protein Ulk1, led to increased intracellular accumulation of phagocytosed myelin 31 
and progressive MS-like disease. This impairment correlated with a microglial phenotype 32 
previously associated with neurodegenerative pathologies. Moreover, Atg7-deficient microglia 33 
showed striking transcriptional and functional similarities to microglia from aged wild-type mice 34 
that were also unable to clear myelin and recover from disease. In contrast, induction of autophagy 35 
in aged mice using the disaccharide trehalose ubiquitously found in plant-based diets, led to 36 
functional myelin clearance and disease remission. Our results demonstrate that a non-canonical 37 
form of autophagy in microglia is responsible for myelin degradation and clearance leading to 38 
recovery from MS-like disease, and that boosting this process has a therapeutic potential for age-39 




Multiple Sclerosis (MS) is a chronic disease characterized by inflammation in the central nervous 42 
system (CNS) that triggers demyelination, glial cell dysfunction and irreversible neuro-axonal 43 
damage (1). While recent understanding of this immune dysfunction has led to the development of 44 
effective disease-modulatory treatments for inflammatory-active relapsing-remitting phase of MS, 45 
there is only one recently approved treatment for secondary progressive phase (2). Disease 46 
progression is not only the most clinically challenging aspect of MS, but it is the least 47 
mechanistically explored. Microglia activation, mitochondrial damage and ionic imbalance, among 48 
other mechanisms, have been associated with progressive neurodegeneration during MS (3). 49 
Progressive MS exhibits a degenerative disease phenotype with glial cell dysfunction rather 50 
than infiltration of peripheral immune cells (4). In MS, microglia express an increased pro-51 
inflammatory profile with both age and disease-burden (4). Age is the strongest risk factor for 52 
developing progressive MS (5). Many age-associated neurodegenerative pathologies such as 53 
Alzheimer’s disease (AD) (4, 6-8), as well as autoinflammatory diseases including Crohn´s disease 54 
and Systemic Lupus Erythematosus (SLE) (9, 10), are characterized by impaired autophagy, a 55 
lysosomal degradation pathway used for removal of cellular constituents. Indeed, microglia 56 
surrounding MS lesions exhibit enhanced autophagy (11) and have the ability to phagocytose 57 
oligodendrocytes, as recently shown by single-nucleus RNA-sequencing (12). While among CNS 58 
myeloid cells microglia have been ascribed the highest phagocytic activity (13), the underlying 59 
mechanisms and their association with MS progression or tissue repair remain to be characterized.   60 
Canonical autophagosome formation is highly dependent on the Unc-51-Like Kinase 1 61 
(ULK1)-complex formation, as well as on Autophagy Related Protein 7 (ATG7) lipidation of LC3, 62 
the key component of autophagosomes. In addition, LC3 can also be conjugated to membranes of 63 
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phagosomes and endosomes, thereby facilitating the degradation of their cargo during processes 64 
termed LC3-associated phagocytosis and endocytosis, respectively (14-16), broadly referred to as 65 
non-canonical autophagy hereafter. Non-canonical autophagy is dependent on the protein 66 
RUBICON (17), which also inhibits the canonical autophagy pathway (18). Mutations in the 67 
Rubicon gene are associated with a familial form of ataxia with impaired lysosomal degradation 68 
(19, 20). Furthermore, inhibition of non-canonical autophagy in macrophages elicited by deletion 69 
of either Atg7 or Rubicon causes an SLE-like disease in mice due to defective degradation of 70 
phagocytosed apoptotic cells (21). Similarly, specific impairment of non-canonical autophagy in 71 
microglia has been associated with reduced clearance of β-amyloid and progressive 72 
neurodegeneration in a murine model of AD (16), also evident in Atg7 deficient mice (22). While 73 
targeting microglial autophagy in these diseases has been proposed to have great therapeutic 74 
potential (8), whether canonical or non-canonical autophagy impacts disease progression in MS is 75 
currently unknown.  76 
We previously established a link between Atg7 and disease severity in a common animal 77 
model of MS, experimental autoimmune encephalomyelitis (EAE) (23). Herein we pinpoint this 78 
effect to microglia, and we reveal how processing of myelin debris by microglia is dependent on 79 
ATG7 in a non-canonical form of autophagy. We further establish this process as a determinant of 80 
microglial phenotype in disease and aging and demonstrate how therapeutically inducing this 81 




Microglial Atg7 deficiency prevents recovery from EAE 84 
To investigate the association between Atg7 and EAE, we deleted Atg7 from two compartments 85 
highly relevant for disease pathogenesis, T cells and myeloid cells, using CRE recombinase 86 
expressed under Lck and Lyz2 promoters, respectively (fig. S1). Deletion of Atg7 in T cells did not 87 
affect clinical disease, although we did observe a previously reported reduction in CD8+ T cell 88 
numbers (24) (fig. S1, A and B). In contrast, deletion of Atg7 in Lyz2-expressing myeloid cells led 89 
to a persistent disease state that lacked the recovery evident in wild-type control mice (fig. S1C). 90 
Lyz2Cre targets several myeloid cell types including microglia (fig. S1D) (22, 25, 26), and the effect 91 
of Atg7 deletion was restricted to the EAE recovery phase, suggesting CNS-intrinsic regulation. 92 
We detected the highest expression and most prominent Atg7 u-regulation during EAE in CD11b+ 93 
CD45Int cells (microglia) compared to other Lyz2-expressing CNS myeloid populations (Fig. 1A). 94 
Expression of the floxed Atg7 exon 14 was dramatically reduced in microglia of Atg7fl/fl Lyz2Cre 95 
mice after EAE induction (fig. S1E). In addition, microglia from these mice displayed reduced 96 
lipidated membrane-bound LC3B (II) (fig. S1F), indicating less autophagosome formation and 97 
lysosomal loading of myelin after in vitro exposure (fig. S1G).  98 
To test the hypothesis that microglial ATG7 plays a role in EAE progression, we utilized 99 
Atg7 deletion under a tamoxifen-inducible CRE recombinase expressed under the Cx3cr1 100 
promoter. Tamoxifen-induced deletion is sustained in the self-renewing microglia population while 101 
other Cx3cr1-expressing cells essential for EAE such as monocytes and dendritic cells are derived 102 
from bone marrow precursors and repopulated from the bone marrow after 2-4 weeks (fig. S2A) 103 
(27). In all experiments, EAE was induced 4-8 weeks after tamoxifen treatment. Deletion of Atg7 104 
exon 14 in Atg7fl/fl Cx3cr1CreERT2 microglia was confirmed at both 2 and 42 weeks after tamoxifen 105 
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administration (fig. S2B), as was reduced ATG7 protein expression (fig. S2C). Atg7fl/fl 106 
Cx3cr1CreERT2 mice exhibited a dramatic loss of recovery from EAE, confirming our hypothesis of 107 
a microglia-dependent phenotype (Fig. 1B).  108 
 109 
Atg7 deficiency impacts microglial tissue debris clearance through non-canonical autophagy 110 
As ATG7 is essential for both canonical and non-canonical autophagy (14, 17), we compared 111 
phenotypes of Atg7fl/fl Cx3cr1CreERT2 mice with mice in which microglia were deficient in Ulk1, a 112 
protein only required for canonical autophagy (21). The Ulk1fl/fl Cx3cr1CreERT2 mice did not exhibit 113 
lack of recovery from EAE, suggesting that impaired non-canonical autophagy drives the disease 114 
phenotype in Atg7fl/fl Cx3cr1CreERT2 mice (Fig. 1C). This notion was further supported by the finding 115 
that microglia from both strains displayed reduced but comparable levels of starvation-induced 116 
canonical autophagy, as evident by decreased membrane-bound LC3B (II) (Fig. 1D) and increased 117 
IL-1β secretion and mitochondrial membrane potential (fig. S2, D and E). This reflects an 118 
impairment in typical canonical autophagy functions in securing mitophagy and inflammasome 119 
stability (22, 28-31). In addition, we determined the key regulator of non-canonical autophagy, 120 
Rubicon (17), to accompany elevated Atg7 expression in wild-type microglia after disease 121 
induction (Fig. 1E and table S1).  122 
Deficiency in non-canonical autophagy has been associated with impaired degradation of 123 
bacterial proteins during infection as well as with impaired phagocytosis of apoptotic cells and β-124 
amyloid, leading to SLE-like disease and AD, respectively (16, 20-22, 32). Indeed, Atg7fl/fl 125 
Cx3cr1CreERT2 microglia displayed a dramatically increased load of intracellular myelin detected ex 126 
vivo during EAE (Fig. 1F). The ex vivo EAE microglia also exhibited reduced autophagosome 127 
formation detected as membrane-bound intracellular LC3B (II) after selective digitonin 128 
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permeabilization (Fig. 1G). Immunofluorescence of microglia sorted 5 days after EAE induction, 129 
when microglia were activated but had not yet accumulated endogenous myelin load, confirmed 130 
the increased load of fluorescently-labeled myelin and decreased LC3 co-localization to myelin-131 
containing vesicles in Atg7fl/fl Cx3cr1CreERT2 compared to Ulk1fl/fl Cx3cr1CreERT2 and wild-type 132 
control mice (Fig. 1H).  133 
To further validate the impaired degradation of the phagocytosed debris in Atg7 deficient 134 
microglia, we pulsed microglia with myelin stained with both a lipophilic dye (CellVueTM) and a 135 
pH-sensitive dye (pHrodoTM). Microglia were sorted ex vivo after immunization, circumventing 136 
the need for further stimulations, and we limited all incubations to ≤ 48h in order to minimize in 137 
vitro culture-induced changes of the microglial phenotype (33). We observed a decreased 138 
pHrodoTM signal in Atg7fl/fl Cx3cr1CreERT2 microglia accompanied by increased CellVueTM (Fig. 139 
1I), indicating impaired degradation in Atg7fl/fl Cx3cr1CreERT2 microglia. This finding was further 140 
demonstrated using time-lapse imaging of microglia pulsed with labeled myelin, revealing an 141 
accumulation of phagocytosed myelin in Atg7fl/fl Cx3cr1CreERT2 microglia (Movie S1).  142 
The impaired loading to degradation vesicles was also observed when Atg7fl/fl Cx3cr1CreERT 143 
microglia were provided irradiated apoptotic CD171+ (neurons), GLAST+ (astrocytes) or O4+ 144 
(oligodendrocytes) cells (fig. S2F). Further analysis demonstrated a dramatically reduced clearance 145 
capacity of myelin debris from medium by microglia from Atg7fl/fl Cx3cr1CreERT2 compared to 146 
Ulk1fl/fl Cx3cr1CreERT2 and wild-type control mice following pulsed exposure to fluorescently-147 
labeled myelin (Fig. 1J). Taken together, our data suggest that an impairment in microglial 148 
autophagy-associated degradation of phagocytosed myelin compromises the clearance of myelin 149 




Microglial Atg7 deficiency drives an altered transcriptional phenotype  152 
To obtain a comprehensive overview of the consequences of Atg7 deletion during EAE, we 153 
performed RNA sequencing of microglia sorted from naïve mice at 21- and 35-days post-induction 154 
of disease (p.i.). We detected 467 and 147 differentially expressed genes (DEG) (adj. p-value < 155 
0.05, fold change > 1.5) between Atg7fl/fl Cx3cr1CreERT2 and littermate controls on days 21 and 35 156 
p.i., respectively (table S1). Only 13 DEGs were detected (adj. p-value < 0.05, fold change > 1.5) 157 
between the genotypes in naïve microglia, suggesting that differences predominantly arise during 158 
EAE (table S1). We clustered DEGs (p < 0.01, fold change > 1.5) and then grouped the clusters 159 
based on their expression patterns (Fig. 2A), performing functional annotation of the groups using 160 
IPA, ORA and REViGO (34, 35) (table S2). The first group (orange) represented changes 161 
considerably more pronounced in Atg7fl/fl Cx3cr1CreERT2 microglia that occurred early in disease 162 
(day 21 p.i.) and returned to levels in the naïve state by day 35 p.i. (Fig. 2A). These changes 163 
associated with pathways typical for activation of immune cells during EAE, such as IFN-γ-, 164 
STAT3- and GM-CSF-signaling, cell activation, expansion and migration (Fig. 2B). The second 165 
group (blue) represented genes that remained downregulated during disease, with Atg7fl/fl 166 
Cx3cr1CreERT2 microglia showing modest changes (Fig. 2A). Functionally, this group was enriched 167 
in pathways involved in myeloid cell function such as quantity, movement, and degranulation of 168 
myeloid cells, as well as activation of GATA2, which is important for the development of myeloid 169 
lineage cells (Fig. 2B). Genes in the third group (yellow) had a similar pattern to the first group in 170 
wild-type but not in Atg7fl/fl Cx3cr1CreERT2 microglia, which demonstrated the opposite pattern (Fig. 171 
2A). These changes are predominantly associated with energy-related functions such as glycolysis 172 
and mitochondrial function, oxidative stress and cell adhesion (Fig. 2B and fig. S3). The fourth 173 
group (purple) represented genes that gradually increased their expression during disease 174 
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progression specifically in Atg7fl/fl Cx3cr1CreERT2 microglia (Fig. 2A). These genes are associated 175 
with cellular growth, including protein synthesis, EIF2- and mTOR-signaling, and were closely 176 
related to microglial development and function in CNS pathology (36) (Fig. 2B and fig. S3). The 177 
functional differences between the groups translated into differential disease enrichment, with early 178 
changes associating with inflammatory and infectious diseases, whereas changes in the progressive 179 
stage of EAE demonstrated strong enrichment in neurodegenerative diseases (Fig. 2C). These 180 
patterns resemble the course of MS, with the initial phase being dominated by inflammatory 181 
processes followed by neurodegeneration that, in later disease stages, becomes decoupled from the 182 
initial inflammation (1). 183 
Atg7fl/fl Cx3cr1CreERT2 microglia exhibited pronounced but transient changes during early 184 
disease (Fig. 2, A and B, orange and yellow) that translated into altered microglia function and 185 
EAE development. These transcriptional profiles associated with immune cell activation and 186 
migration, reflected in increased microglia numbers and a more robust infiltration of bone marrow-187 
derived macrophages (BMDMs), neutrophils, and T and B cells into the CNS parenchyma during 188 
early EAE (Fig. 3A). In accordance with IFN-γ and TNF predicted to be activated upstream 189 
regulators (Fig. 2B and table S2), a larger proportion of infiltrating T cells in Atg7fl/fl Cx3cr1CreERT2 190 
mice were IFN-γ+ (fig. S4A). Atg7fl/fl Cx3cr1CreERT2 microglia themselves secreted dramatically 191 
larger amounts of IFN-γ, TNF and IL-1β (Fig. 3B), the latter suggesting activation of the 192 
inflammasome as previously reported to occur in response to myelin accumulation (37). Moreover, 193 
Atg7fl/fl Cx3cr1CreERT2 microglia were capable of stimulating T cell proliferation and expansion of 194 
pathogenic IFN-γ-producing cells in vitro (fig. S4, B-D). Atg7 deficiency promoted a microglial 195 
phenotype that can augment inflammatory responses during EAE (fig. S4).  196 
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In MS patients, an increased inflammatory activity during the first 2 years after diagnosis 197 
has been associated with the risk of clinical progression during early disease (38). Long-term 198 
disability, nevertheless, better correlates with brain atrophy, reflecting neuro-axonal loss (39, 40). 199 
Interestingly, Atg7 deletion resulted in a microglial phenotype that associated with neuronal 200 
function and neurodegenerative diseases (4), suggesting sustained transcriptional changes that are 201 
critical for disease progression (Fig. 2, A and C, purple). Indeed, a late stage transcriptional profile 202 
of Atg7fl/fl Cx3cr1CreERT2 microglia demonstrated a remarkable enrichment in microglial genes 203 
associated with neurodegenerative diseases (4, 41) and MS-associated microglia identified in 204 
recent single-cell RNA-sequencing studies (42, 43) (Fig. 3C, fig. S5 and table S3). We confirmed 205 
differences in protein levels of CLEC7A and CD11c/ITGAX (fig. S6A). In contrast, the 206 
homeostatic and tolerogenic state genes (4, 44) were depleted in Atg7fl/fl Cx3cr1CreERT2 microglia 207 
(Fig. 3C and fig. S5).  208 
 209 
Microglia deficient in Atg7 have impaired signs of debris uptake and degradation  210 
The Clec7a gene encodes the C-type lectin Dectin-1, which is known to induce LC3-associated 211 
phagocytosis and recognizes ligands released upon CNS damage (45-48). Clec7a expression 212 
characterizes a microglia population associated with neurodegenerative conditions (4). Atg7fl/fl 213 
Cx3cr1CreERT2 showed dramatically increased number of CLEC7A+ IBA1+ microglia compared to 214 
control mice (Fig. 3D and fig. S6B).   215 
We observed that Atg7 deletion did not affect the frequency of the CLEC7Aint population, 216 
but it did lead to a near loss of CLEC7Alow and a robust increase in CLEC7Ahigh cells (Fig. 3, E 217 
and F).  CLEC7Ahigh, and in particular CLEC7Aint, microglial populations displayed dramatically 218 
lower surface expression of the scavenging receptors MSR1 (SR-A, CD204) (Fig. 3G), CD36 and 219 
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other receptors (e.g. CD200R, IA/IE) that are implicated in microglial function during 220 
inflammation (49-51) (fig. S6C). We further demonstrated that myelin phagocytosis relies, at least 221 
in part, on uptake mediated by MSR1, because the uptake of pHrodo-labelled myelin by microglia 222 
in vitro could be blocked using an MSR1 antibody (Fig. 3H), and myelin induced robust surface 223 
expression of MSR1 (Fig. 3I). Interestingly, whereas RNA-sequencing implicated an increased 224 
Msr1 expression in Atg7fl/fl Cx3cr1CreERT2 microglia (fig. S6D), flow cytometry analysis revealed 225 
reduced surface receptor quantity (fig. S6E). A similar pattern was observed for CD36 (fig. S6, D 226 
and F). However, a pool of intracellular MSR1 was detected upon permeabilization (Fig. 3J), 227 
suggesting a blocking of retrograde trafficking of phagosomal receptors that has been described in 228 
the context of disrupted non-canonical autophagy (16). To confirm this we blocked the fusion of 229 
phagosomes and lysosomes in microglia ex vivo using Bafilomycin A1, which resulted in an 230 
increase in intracellular MSR1 and CD36 levels (Fig. 3I and fig. S6G). These data indicate that 231 
stalling myelin-loaded autophagosomes can lead to MSR1 retention that could further sustain 232 
microglial failure to clear myelin debris, as observed after repeated myelin pulsing (Fig. 1J). This 233 
pattern of intracellular accumulation in relation to myelin exposure and genotype was not detected 234 
upon targeting other potential myelin scavenger receptors such as CR3, CD16, CD64 or MARCO 235 
(fig. S6H).  236 
Transcriptomic alterations of late stage microglia further supported the notion of impaired 237 
phagosomal degradation in Atg7-deficient microglia. A marked upregulation of apolipoprotein E 238 
(Apoe) was observed in late-stage Atg7fl/fl Cx3cr1CreERT2 microglia by RNA-sequencing (Fig. 3K), 239 
together with other lipoproteins (Apoc1, Apoc4) and lipoprotein lipase (Lpl) (fig. S6I). 240 
Upregulation of APOE occurs in response to the binding of myelin-derived cholesterol to the 241 
endogenous liver X receptor (LXR), which is transcriptionally activated in Atg7fl/fl Cx3cr1CreERT2 242 
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microglia (Fig. 2B) and is crucial for the export of cholesterol from microglia to the extracellular 243 
space (37). Moreover, we observed increased expression of Apoe when phagosome-lysosome 244 
fusion was impaired using bafilomycin A treatment (Fig. 3K), again suggesting that Apoe 245 
upregulation in Atg7fl/fl Cx3cr1CreERT2 microglia constitutes a response to intracellular myelin 246 
accumulation. We also observed that TREM2, which can bind APOE and other lipids (52) and is 247 
an inducer of the APOE pathway (4) and plays a major role in recovery from EAE (53), was 248 
upregulated during late EAE stages (fig. S6J), and that the pathway of TREM2 was highly activated 249 
(fig. S5). Finally, levels of TGF-β1, a marker of homeostatic microglia as opposed to LXR-APOE-250 
TREM2 disease-associated microglia (4, 54), was dramatically decreased in Atg7fl/fl Cx3cr1CreERT2 251 
microglia (Fig. 3L). Atg7fl/fl Cx3cr1CreERT2 microglia thus appear to cope with increase myelin load 252 
by engaging the LXR-APOE-TREM2 pathway and by upregulating the expression of the MSR1 253 
and other scavenging receptors to compensate for reduced retrograde transport and failed myelin 254 
degradation.  255 
Accumulation of myelin debris is a strong inhibitor of oligodendrocyte differentiation and 256 
remyelination, suggested to hinder recovery from inflammatory insults during MS and EAE and 257 
leads to neuro-axonal loss (55, 56). Indeed, staining of Atg7fl/fl Cx3cr1CreERT2 microglia ex vivo with 258 
an antibody against degraded myelin basic protein (dMBP) revealed an accumulation of this protein 259 
in late stage disease compared to microglia from control animals (Fig. 3M). Immunostaining of 260 
spinal cords further demonstrated the accumulation of dMBP in tissue, which overlapped with areas 261 
of activated microglia/infiltrating BMDMs (MAC3 bright) (Fig. 3N and fig. S7A). This was 262 
accompanied by unresolved inflammation evident as increased representation of immune cells 263 
during late stage EAE (fig. S7, B and C). Moreover, pulsing late stage Atg7fl/fl Cx3cr1CreERT2 264 
microglia with myelin ex vivo led to lower uptake as compared to microglia from control animals 265 
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(fig. S7D). We addressed whether the increased pool of tissue infiltrating BMDMs (fig. S7C) could 266 
compensate for the reduced phagocytic capacity in Atg7fl/fl Cx3cr1CreERT2 mice, but BMDM cells 267 
underperformed microglia in phagocytosis of myelin as assessed by both ex vivo myelin load in 268 
cells isolated from late disease stage as well as by an in vitro myelin clearance assay (fig. S7, D 269 
and E). Finally, flow cytometry assessment of oligodendrocytes isolated from the spinal cord at 270 
this time point confirmed a lower frequency of CD45-GALC+MOG+ myelinating cells in Atg7fl/fl 271 
Cx3cr1CreERT2 animals as compared to controls (fig. S7F). Accordingly, we recorded reduced 272 
myelination in the Atg7fl/fl Cx3cr1CreERT late stage EAE spinal cords (fig. S7G). Atg7-dependent 273 
impairment of microglia needed to clear myelin upon an inflammatory demyelinating insult could 274 
not be compensated for by infiltrating phagocytes and was associated with reduced CNS 275 
myelination during late stage disease.  276 
 277 
Aged microglia recapitulate the phenotype of young Atg7-deficient microglia 278 
Since age is the strongest risk factor for progressive MS (5, 57) and as many age-associated 279 
neurodegenerative pathologies are characterized by impaired autophagy (4, 6-8), we compared the 280 
impact of Atg7 deficiency in the context of aging. We observed a remarkable similarity between 281 
the transcriptomes of Atg7fl/fl Cx3cr1CreERT2 microglia and microglia from aged mice (> 80 weeks) 282 
compared to control young microglia (Fig. 4A and table S4). Both late disease stage microglia from 283 
Atg7fl/fl Cx3cr1CreERT2 mice and microglia from aged (> 80 weeks) wild-type mice revealed 284 
enrichment of genes associated with microglia during neurodegenerative diseases (4, 41), as well 285 
as MS-associated microglia (42, 43) (fig. S5). Accordingly, aged mice developed aggravated EAE 286 
with a clinical course similar to that of Atg7fl/fl Cx3cr1CreERT2 mice (Fig. 4B) and exhibited signs of 287 
accumulated myelin load (Fig. 4C). Similar to Atg7fl/fl Cx3cr1CreERT2, in vitro time-lapse imaging 288 
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demonstrated that microglia from aged mice had reduced lysosomal loading of myelin as assessed 289 
by co-localization with low pH-sensing dye (pHrodoTM) and the pH-indifferent dye (PKH26TM), 290 
the latter detecting accumulation of myelin-containing phagosomes (Movie S2). 291 
 292 
Trehalose boosts autophagy in aged microglia and promotes recovery from EAE 293 
While increased understanding of the immune dysfunction during early relapsing-remitting phases 294 
of MS has led to the recent development of effective disease-modulatory treatments, progressive 295 
stages still largely lack treatment options. In accordance with our data, boosting microglial 296 
autophagy in neurodegenerative diseases has been proposed to have considerable therapeutic 297 
potential (58-60). However, whether this could have beneficial effects in MS, and whether 298 
canonical or non-canonical autophagy is involved in disease progression, is currently unknown. To 299 
target phagocytosed myelin through autophagy we administered trehalose, a disaccharide known 300 
to induce autophagy and ameliorate age-associated diseases (61-66). Daily trehalose administration 301 
starting 1 week before EAE induction led to a reduction in the clinical severity of EAE, and more 302 
than 40% of aged control mice recovered as well as aged Ulk1fl/fl Cx3cr1CreERT2 mice that have 303 
compromised canonical autophagy (Fig. 1D, Fig. 4B and fig. S8A). We did not observe any 304 
trehalose effect on clinical EAE in younger mice, regardless of the genotype, nor in aged Atg7fl/fl 305 
Cx3cr1CreERT2 mice (Fig. 4B and fig. S8A), suggesting that trehalose acts by boosting non-canonical 306 
autophagy. Indeed, we observed that trehalose increased nuclear density of TFEB, a key 307 
transcription factor for autophagy and lysosome-associated genes (61), and an increased formation 308 
of lysosomes defined by LAMP1, a major lysosome membrane component (Fig. 4D). We also 309 
detected increased expression of multiple autophagy and lysosome genes upon trehalose treatment 310 
of aged microglia (Fig. 4E).  311 
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Following trehalose treatment, we detected a reduction of intracellular microglial 312 
myelin load in aged EAE mice ex vivo (Fig. 4C), and increased myelin clearance and degradation 313 
through lysosomes in vitro (Fig. 4, F and G). Trehalose treatment also reduced the frequency of 314 
disease-associated microglia defined by expression of CLEC7A and APOE (Fig. 4H) as well as the 315 
infiltration of BMDMs (fig. S8B). Furthermore, microglia from trehalose-treated aged mice 316 
displayed reduced secretion of the disease-associated cytokines IFN-γ, TNF and IL-1β, and 317 
increased TGF-β1 secretion that reflected a normalization of the profile evident in microglia from 318 
young mice (Fig. 4I). Taken together we validated an age effect on autophagy-associated vesicular 319 
biogenesis, with a decline in lysosome loading of phagocytosed myelin debris, similar to that in 320 
Atg7fl/fl Cx3cr1CreERT2 microglia. In aged mice this impairment was successfully mitigated with 321 
trehalose treatment, with consequent effects on transcription, lysosome biogenesis, cytokine 322 




We herein demonstrate that a non-canonical form of autophagy in microglia is responsible for 325 
myelin degradation and clearance and that impairment of this pathway, which occurs during aging, 326 
contributes to the progression of MS-like disease. Importantly, we show that we can modulate this 327 
process therapeutically, with implications in other age-related neuroinflammatory disease. 328 
The cellular events underlying inflammatory bouts typical of MS and EAE are well 329 
characterized, while the events promoting resolution of inflammation and limiting progression are 330 
much less understood (67). However, accumulation of myelin and inflammatory debris in the target 331 
tissue are known factors with inhibitory effects on remyelination (55, 56). We now demonstrate 332 
that the impaired myelin clearance capacity of microglia leads to increased tissue deposits of 333 
myelin debris accompanied by reduced myelination and oligodendrocyte differentiation. The 334 
deletion of Atg7 in microglia caused persistent neuroinflammation and, by comparing Atg7fl/fl 335 
Cx3cr1CreERT2 mice with Ulk1fl/fl Cx3cr1CreERT2, we demonstrated that the phenotype was largely 336 
independent from canonical autophagy. In several in vivo and in vitro experimental settings, we 337 
observed that the lack of Atg7 drives microglial dysfunction in clearance and processing of myelin 338 
debris and apoptotic CNS cells. The reduced clearance capacity of the microglia is most likely a 339 
consequence of internalization of scavenger receptors due to impaired Atg7-dependent lysosomal 340 
degradation.  341 
Our model presented an opportunity to study impaired degradation of phagocytosed 342 
components as a regulator of microglial phenotype, which is relevant for a broad range of myeloid 343 
cell-associated pathologies. The elevated infiltration of peripheral immune cells 21 days after EAE 344 
induction was associated with an altered Atg7fl/fl Cx3cr1CreERT2 microglial cytokine profile, likely 345 
in synergy with increased myelin tissue deposits and local CNS expansion of immune cell 346 
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populations. Interestingly, the infiltrating macrophage population did not compensate for the 347 
reduced myelin clearance of Atg7fl/fl Cx3cr1CreERT2 mice. In fact, the capacity for myelin clearance 348 
of this population at a late disease stage was dramatically lower than that of microglia, which 349 
corroborates previous findings (13) and supports the established idea of microglia being promoters 350 
of homeostasis, in contrast to the monocyte-derived macrophages which exhibit a more 351 
inflammatory phenotype (68). 352 
Although the day 21 EAE microglia of Atg7fl/fl Cx3cr1CreERT2 mice reflect an acute 353 
inflammatory state, the day 35 microglia represent a more unique phenotype relevant for evaluating 354 
the challenges of chronic inflammation and tissue degeneration. The microglial transcriptome from 355 
persistent EAE at day 35 in Atg7fl/fl Cx3cr1CreERT2 mice was similar to other reported disease-356 
associated microglial transcriptomes, indicating shared microglial pathology (4, 41). Potentially 357 
pathogenic microglia are dependent on the TREM2-APOE axis (4, 69). In our Atg7fl/fl Cx3cr1CreERT2 358 
day 35 EAE microglia, we observed an enriched TREM2 pathway accompanied by elevated Apoe 359 
expression ex vivo and in vitro as a consequence of increased intracellular myelin load. Intracellular 360 
lipids are sensed by LXR which acts as a transcription factor inducing Apoe expression. We 361 
propose an LXR-mediated pathogenic feed-forward mechanism through APOE in which 362 
intracellular myelin is not functionally degraded. The enriched LXR pathway in Atg7fl/fl 363 
Cx3cr1CreERT2 microglia resembled the macrophage phenotype characteristic of atherosclerosis, a 364 
disease state in which there is pathogenic accumulation of intracellular lipid compounds (64). 365 
Phagocytosis of tissue debris has been reported to be essential for the maintenance of tissue 366 
homeostasis (70), and we demonstrate that upon inflammation the re-establishment of an anti-367 
inflammatory response and subsequent tissue recovery are curbed when phagocytosis is decoupled 368 
from downstream cargo degradation through non-canonical autophagy. Expression of molecules 369 
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associated with disease states (e.g. CLEC7A, CD11c) was increased in Atg7fl/fl Cx3cr1CreERT2 370 
microglia while the expression of genes that characterize homeostatic microglia was reduced (e.g. 371 
P2Ry12, CSF1R, CD200R, MSR1, TGF-β1) (54). Among these, CLEC7A is of great interest as it 372 
is a strong inducer of LC3-associated phagocytosis (47, 48). Elevated expression of CLEC7A 373 
reported here for EAE and previously associated with pathology-associated microglia in other 374 
models (4) is therefore directly linked to an important functional outcome.  375 
Increased age leads to a decline in autophagy and is a risk factor for progressive MS and 376 
neurodegeneration (57, 71). Dysfunctional aged myeloid cells have been reported in other settings 377 
to be a consequence of inefficient autophagy (72). We thus explored the potential of induced 378 
autophagy in ameliorating age-associated aggravated EAE disease. Treatment with the autophagy-379 
inducing disaccharide trehalose led to a robust recovery rate and decline in clinical symptoms in 380 
aged mice, reminiscent of the recovery characteristic of untreated young wild-type mice (65, 73). 381 
However, trehalose treatment did not affect recovery of young wild-type mice or Atg7fl/fl 382 
Cx3cr1CreERT2 mice, suggesting that non-canonical autophagy in microglia from young mice is 383 
already at sufficient capacity, and that the effect of trehalose treatment in aged mice is dependent 384 
on microglial ATG7, regardless of whether trehalose exerts its effect upstream or downstream of 385 
ATG7. The trehalose treatment induced vesicle biogenesis through transition of transcription factor 386 
TFEB to the nucleus, increased lysosome density and myelin clearance and degradation. Trehalose 387 
treatment in vivo also reduced the density of CNS infiltrating bone marrow-derived macrophages 388 
during EAE and a reduced pro-inflammatory cytokine profile evident in microglia from aged mice.  389 
The tools for defining and studying microglia have developed vastly over the past years, 390 
allowing for more accurate ex vivo and in vitro experiments, which however have an impact on the 391 
microglial phenotype, especially regarding contextual and dynamic processes such as autophagy. 392 
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Another challenge for future work is the characterization of autophagy-associated phagocytosis in 393 
humans, especially in disease context as in progressive human neuroinflammation. Additional 394 
work on molecules of the microglial autophagy-associated phagocytosis including RUBICON 395 
would also add support to our findings and could unveil interesting pharmacological targets. 396 
Finally, the phenotypes observed on autophagy-deficient microglia could partially stem from 397 
secondary effects such as increased phagosome load which also warrants further exploration. 398 
Taken together our findings demonstrate that degradation of inflammatory myelin debris 399 
by microglia is dependent on the non-canonical arm of autophagy, a function necessary for cell and 400 
CNS tissue homeostasis. We thus provide a functional link between age, autophagy and myeloid 401 
dysfunction. We associate our phenotype with the newly described microglial transcriptomes 402 
primarily described in neurodegenerative diseases, suggesting a shared pathology and providing a 403 
functional characterization. Finally, we propose this pathway to be as a promising treatment target 404 




Materials and Methods 407 
 408 
Study design  409 
Previous work by our lab established a link between Atg7 and disease severity in EAE, an animal 410 
model for MS (23). In this study, we set out to understand whether this effect was intrinsic to the 411 
immune system by broadly targeting the deletion of Atg7 in mice to either T cells or myeloid cells 412 
by crossing Atg7-floxed mice to LckCRE or Lyz2CRE expressing strains, respectively. Since the effect 413 
of the deletion was observed during the recovery phase of EAE, which pointed to effects within 414 
the CNS, we further restricted Atg7 deletion to microglia and CNS-resident macrophage 415 
populations by crossing Atg7-floxed mice to a Cx3cr1CreERT2 expressing strain (see Experimental 416 
subjects section). Experiments were performed with littermate controls, using both males and 417 
females. Animals were randomized and the majority of analysis was done in a blinded fashion. 418 
Sample sizes varied depending on the goal of each experiments (i.e. dissection at one or multiple 419 
timepoints, in vitro cultures, etc.) and expected effect sizes, and numbers of animals as well as 420 
statistical analysis methods are thus given in each figure for every experimental setup. No animals 421 
were excluded from analyses apart from two samples in RNA-sequencing that did not have correct 422 
genotype. Catalogue numbers and the description of different primers, antibodies and kits used 423 
throughout the study can be found as an additional technical sheet (table S5).    424 
 425 
Ethics Statement 426 
Animal experiments were approved and performed in accordance with the guidelines from the 427 
Swedish National Board for Laboratory Animals and the European Community Council Directive 428 
(86/609/EEC) under the ethical permits N284/07 (N332/06), N338/, N138/14, N1387/14 and 9328-429 
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2019 which were approved by the North Stockholm Animal Ethics Committee (Stockholms Norra 430 
djurförsöksetiska nämnd). Mice were tested according to a health-monitoring program at the 431 
National Veterinary Institute (Statens Veterinärmedicinska Anstalt, SVA) in Uppsala, Sweden.  432 
 433 
Experimental Subjects 434 
Gene-deleted mice on the C57BL/6 background were generated by cross-breeding of Atg7fl/fl or 435 
Ulk1fl/fl to LckCRE, Lyz2CRE or Cx3cr1CreERT2 transgenic mice. All strains were purchased from The 436 
Jackson Laboratory except Atg7fl/fl that was a gift from Dr. Klas Blomgren. All experimental Cre 437 
mice had a hemizygote genotype. Cx3cr1CreERT2 mice were treated with 4mg tamoxifen (TAM; 438 
Sigma), dissolved in corn oil and administrated subcutaneously three times, at 48-hour intervals. 439 
Experiments were initiated at earliest 4 weeks after the first tamoxifen administration to allow for 440 
repopulation of peripheral bone marrow-derived Cx3cr1CreERT2 expressing cells such as monocytes, 441 
while the gene deletion effect is preserved in the self-renewing CNS resident microglial population. 442 
While border associated macrophages in meninges and perivascular spaces also express Cx3cr1, 443 
self-renew and are targeted by TAM administration, they have been shown not to contribute to T 444 
cell activation and CNS damage during EAE and are absent in the parenchyma where the processes 445 
of myelin uptake and degradation described in this paper occur(74, 75). No dramatic influence 446 
from the Atg7fl/fl allele or Cre+/- toxicity was observed. In EAE experiments, 10-18 weeks old 447 
littermate mice were used. Aged mice were > 80 weeks old.   448 
 449 
Induction and Clinical Evaluation of EAE 450 
Recombinant mouse myelin oligodendrocyte glycoprotein (rmMOG) aa1-125 from the N-451 
terminus, was expressed in Escherichia coli and purified to homogeneity using chelate 452 
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chromatography, as previously described(76, 77). The purified protein, dissolved in 6M urea, was 453 
dialyzed against PBS. For EAE induction mice were immunized with a single subcutaneous 454 
injection at the dorsal tail base with 100µl of inoculum containing rmMOG, 18-30µg/mouse in 455 
saline solution emulsified in a 1:1 ratio with Complete Freund’s Adjuvant (CFA, Chondrex) 456 
(100µg Mycobacterium tuberculosis/mouse), all under isoflurane (Baxter) anesthesia. 457 
Additionally, all experimental animals received an i.p. injection of 200ng/mouse pertussis toxin 458 
(PTX, Calbiochem) at days 0 and 2 p.i. 459 
The clinical score was graded as follows: 0, no clinical signs of EAE; 1 - tail weakness or tail 460 
paralysis; 2 - hind leg paraparesis or hemiparesis; 3 - hind leg paralysis or hemiparalysis; 4 - 461 
tetraplegia or moribund; 5 - death. EAE remission was calculated as number of mice with full 462 
recovery (score 0) divided by total EAE incidence within the subgroup. 463 
 464 
Single cell suspensions from CNS  465 
CNS cells were extracted using the Neural Tissue dissociation kit T (Miltenyi Biotech). Mice were 466 
anesthetized with isoflurane and transcardially perfused with ice-cold PBS. Brains and spinal cords 467 
were mechanically minced and resuspended in enzyme mix according to the manufacturer’s 468 
protocol. The CNS homogenates were then passed through a 40µm cell strainer and washed with 469 
PBS containing 5mM Ethylenediaminetetraacetic acid (EDTA). The pellet was resuspended in a 470 
38% Percoll (Sigma) solution and centrifuged at 800g for 15 min (no brake). The myelin gradient 471 
layer was extracted and cells resuspended in PBS.  472 
 473 
Cell cultures  474 
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Cells were cultured in Dulbecco’s modified Eagles medium (DMEM, Sigma) conditioned with 475 
Fetal bovine serum 10% (vol/vol) (FBS, Sigma) and Penicillin/Streptomycin 1% (vol/vol) (Sigma) 476 
and M-CSF 20ng/ml (R&D). For the starvation-induced autophagy experiment cells were kept in 477 
Earle’s balanced salt solution (EBSS, Sigma) for 5h before analysis. Bafilomycin A1 (Sigma) was 478 
used in concentration of 1M.   479 
 480 
Flow cytometry 481 
CNS cells were analyzed at several time points from naive to day 35 p.i. EAE. Single-cell 482 
suspensions were plated and stained with conjugated antibodies and LIVE/DEAD™ Fixable Near-483 
IR Dead Cell Stain (Invitrogen; L34976). Intracellular/Intranuclear staining was performed after 484 
permeabilization using a Fixation/Permeabilization kit (BD biosciences/eBioscience). LC3 was 485 
detected using a digitonin kit causing mild permeabilization, leaving mainly membrane-bound LC3 486 
in the cell for analysis. Mitochondrial membrane potential was quantified using the Mitotracker 487 
deep redTM probe.  Cells were acquired using a Gallios flow cytometer (Beckman Coulter) and 488 
analyzed using Kaluza software (Beckman Coulter).  All antibodies and reagents are specified in 489 
the enclosed technical data file.  490 
Cell sorting 491 
Cells from mouse CNS were sorted using a BD Influx cell sorter. Microglia were sorted as Live, 492 
CD11b+ CD45Intermediate(Int) Ly6G- and/or eYFP+ (fig. S9). Bone marrow-derived macrophages were 493 
sorted as Live CD11b+ CD45High Ly6G- and/or eYFP-. Neutrophils were sorted as Live CD11b+ 494 
Ly6G+ and/or eYFP-. Cells for some in vitro experiments were sorted from naïve or day 5 p.i. 495 
mouse CNS using CD11b magnetic beads and columns (MACS, Miltenyi Biotech). Purity was 496 
determined using flow cytometry to be > 90% YFP+ cells. The purpose of sorting cells from day 5 497 
24 
 
p.i. was to acquire activated microglia without accumulated intracellular myelin phagosomes. 498 
Blood monocytes were sorted using Ly6C magnetic beads (MACS, Miltenyi Biotech). 499 
  500 
Mouse cell RNA, cDNA preparation and Expression Analysis 501 
Cell pellets from sorted mouse CNS cells were lysed in RLT buffer and RNA extracted using a 502 
RNeasy mini kit (Qiagen). Reverse transcription of total RNA was performed using random 503 
hexamer primers (Invitrogen) and Superscript Reverse Transcriptase (Invitrogen). cDNA was 504 
stored at -20°C until use. qPCR was performed in triplicates using a CFX384™ Real-Time PCR 505 
Detection Systems with SYBR green as fluorophore (Bio-Rad). C(t) values with inter-duplicate 506 
differences more than one cycle were excluded. Target expression was calculated using the Bio-507 
Rad CFX Manager V1.6. software. Hprt or the geometrical mean of Gapdh and Hprt was used as 508 
housekeeping gene reference.  509 
 510 
Next-generation sequencing 511 
Sorted microglia were pooled 1:1 female and male. RNA was prepared using a RNeasy Mini Kit 512 
(Qiagen) followed by quality control assessed with a Bioanalyzer 2100 (Agilent). All samples 513 
included had high quality RNA (RIN = 8.5–10). RNA was amplified with a SMARTer Stranded 514 
Total RNA-Seq Kit–Pico Input Mammalian (Clontech). Next-generation sequencing and 515 
generation of bioinformatic data was performed by the National Genomics Infrastructure (NGI) at 516 
the Science for Life Laboratory using a HiSeq 2500 System with a HiSeq Rapid SBS Kit v2 517 
(Illumina). Data normalization and analysis of differential gene expression were performed using 518 
the DESeq2 R package with a negative binomial test(78). The false-discovery-rate-adjusted P value 519 
was estimated using the Benjamini–Hochberg correction(79). Data was further analyzed using 520 
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Ingenuity pathway analysis (IPA, Qiagen) and Gene set enrichment analysis (GSEA, Broad 521 
institute). GSEA analysis performed with standard settings – Classic scoring scheme for the 522 
enrichment score signal2noise metrics for the ranked gene list.  Heat maps show in different figures 523 
show the range of expression values in red – blue (denoting high - low) calculated from normalized 524 
counts. 525 
 526 
Myelin isolation and staining 527 
Pure myelin was obtained using a protocol adapted from Norton and Poduslo (80). Briefly, myelin 528 
was isolated through mechanical homogenization of perfused brains in homogenization buffer with 529 
PBS containing 0.32M sucrose. After two washes in homogenization buffer, an 0.85M sucrose 530 
solution in PBS underlay was added to the CNS homogenate. The CNS gradient was centrifuged 531 
at 4500g for 50 min. The interphase containing myelin was then washed twice in water. The 532 
purified myelin was then incubated with pHrodo dye and/or CellVueTM Plum and /or 533 
FluoromyelinTM (all from Thermo Fischer Scientific) and/or PKH26TM (Sigma) in PBS/Hepes 534 
according to the manufacturer's instructions, followed by washing. 535 
 536 
Immunofluorescence 537 
CNS cells were sorted and plated into poly-L-lysine coated plates and incubated for 36h before 538 
adding purified myelin for an additional 12h. After washing, cells were fixed with 4% PFA and 539 
permeabilized with 0.2% Tween-20. Non-specific binding was blocked by adding 10% BSA and 540 
serum from secondary antibody producing species. Cells were then incubated overnight with 541 
primary antibodies diluted in PBS containing 1% BSA and 0.2% Tween-20. After washing, 542 
secondary antibodies diluted in host serum were added and incubated at 37°C for 1 h. Finally, 543 
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DAPI solution (4′,6-Diamidino-2-Phenylindole, Dihydrochloride, 0.2μg/ml, BD Biosciences) was 544 
added to the wells for 3 min before final washing. Samples were analyzed using a Leica Confocal 545 
microscope and Leica LAS-X software. CellprofilerTM (Broad institute) software was used for 546 
quantitative analysis (analysis pipeline enclosed). Images were acquired using the same settings 547 
for all samples.  548 
 549 
Phagocytosis assays 550 
Phagocytic uptake and loading to low pH lysosomes were quantified by flow cytometry analysis 551 
of ex vivo CNS cells or sorted in vitro myeloid populations. For apoptotic cell phagocytosis panels 552 
CNS cells were sorted using MACS™ kits for either CD171, O4 or GLAST (Miltenyi biotech). 553 
Apoptosis was induced by radiation using a Precision X-rad (1Gy/min at 320KV, 12.5mA) twice 554 
with 8 h incubation pause (Li et al., 1996). pHrodoTM labeled cells were pulsed with stained myelin 555 
or apoptotic cells for 30 min followed by washing and flow cytometry. 556 
 557 
Incucyte time-lapse imaging 558 
Sorted microglia were pulsed with purified myelin stained with pHrodo Green and PKH26. 559 
Incubation plates were immediately transferred to an incubator connected to an Incucyte ZOOMTM 560 
instrument in which wells were analyzed using 20x ocular magnification every hour for 16-28h, 561 
generating time-lapse movies. (Green: Excitation Wavelength: 460 nm, Emission Wavelength: 524 562 
nm. Red: Excitation Wavelength: 585 nm, Emission Wavelength: 635 nm) 563 
 564 
LC3B-II detection and Digitonin permeabilization protocol 565 
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Membrane-bound lipidated LC3 (II) was detected after mild digitonin permeabilization extracting 566 
cytosolic LC3 according to a previously described protocol(81). Cells seeded in 96 well plates were 567 
treated with the non-ionic detergent Digitonin (Sigma) at a concentration of 50g/mL in PBS for 568 
5 min at room temperature. This permeabilizes the membrane for extracellular diffusion of non-569 
bound LC3 while membrane-bound LC3 remains in the autophagosomal membrane. Cells were 570 
then fixed in 4% (w/vol) paraformaldehyde/PBS for 10 min at room temperature. After two washes 571 
in PBS, cells were incubated with an anti-LC3B antibody for detecting membrane-bound LC3B.  572 
 573 
Acid wash stripping of surface molecules 574 
Analysis of receptor internalization was achieved using a protocol for acid-wash stripping of 575 
surface receptors. Cultured cells were detached with EDTA and incubated with PBS containing 576 
glycine (100mM) and NaCl (150mM) (pH 2.5) for 5 min on ice. Cells were then stained and 577 
analyzed by flow cytometry after fixation with or without permeabilization.  578 
 579 
Myelin clearance assay 580 
Sorted ex vivo microglia from immunized mice (day 5 or 21 p.i.) were seeded at 5x104 cells per 581 
well in 96 well plates and incubated for 12 h before PKH26- conjugated myelin was added. At the 582 
indicated timepoints, supernatant was removed and analyzed using a SpectraMax 384 microplate 583 
reader for fluorescence at 560nm. The remaining myelin concentration was determined in relation 584 
to a standard dilution series.  585 
 586 
Microglia-CD4 T-cell co-culture  587 
Sorted ex vivo microglia from immunized mice (day 5 p.i.) were seeded at 2 x104 cells per well in 588 
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96 well plates coated with poly-L-lysine. After 24 h, 2 x104 MACS-sorted CD4+ T cells (Miltenyi 589 
Bioscience) from EAE mice (day 21 p.i.) were added per well. After 36 h cells, cells were analyzed 590 
by flow cytometry after intranuclear Ki67 labeling as a marker of proliferation.  591 
 592 
ELISA 593 
Sorted ex vivo microglia from naive mice and mice during EAE were incubated in DMEM, (Sigma) 594 
conditioned with Fetal bovine serum 10% (vol/vol) (FBS, Sigma) and penicillin/streptomycin 1% 595 
(vol/vol) for 24h in 96 well plates. Supernatants were collected and cytokine production was 596 
quantified using ready-set-go ELISA kits (eBioscience, Invitrogen) and a SpectraMax 384 597 
microplate reader plate reader according to the manufacturer's instructions.   598 
 599 
Trehalose treatment of EAE 600 
For studies of the clinical effects of trehalose, mice were treated with water supplemented with 601 
either 5% (w/vol) D-(+)-trehalose dihydrate or 5% (w/vol) sucrose (both from Sigma) starting at 602 
the day of immunization. Sucrose was used as control given its similarity to trehalose since both 603 
are disaccharides, thus excluding elevated calorie availability as a determinant of EAE recovery. 604 
I.p. injections of 20% (w/vol) trehalose, 20% (w/vol)  sucrose, 20% (w/vol) or PBS supplemented 605 
the treatment every third day starting from EAE onset until end of experiment. During severe EAE, 606 
mice were fed with trehalose, sucrose and water at a final concentration of 20% (w/vol). The i.p. 607 
doses were equal to previously reported clinical experiments while the drinking water was enriched 608 
to 5% (w/vol) trehalose (compared to 3% (w/vol) (62). This was a result of a titration experiment 609 




Trehalose and TFEB in vitro assays 612 
Ex vivo microglia were cultured in medium with or without D-(+)-trehalose dihydrate at a final 613 
concentration of  3% (w/vol). ICC experiments were performed as described above using 614 
antibodies against TFEB (Rabbit, Bethyl, diluted 1:1000) and LAMP1 (Rat, Sigma, diluted 615 
1:1000), which labels lysosomes, and secondary antibodies Alexa fluor 647 goat anti-rat (Thermo 616 
fisher) and goat-anti rabbit Alexa fluor 546 (Thermo fisher), respectively. TFEB and LAMP1+ 617 
lysosomes were quantified in relation to DAPI-defined nuclei (0.2 μg/ml) using CellprofilerTM 618 
software.  619 
 620 
Histopathology and immunofluorescence (IF) 621 
Histopathological and IF analyses were performed on 3–5 μm thick paraffin-embedded spinal cord 622 
cross-sections. Luxol fast blue (Kluever; Sigma) was used to assess tissue 623 
demyelination. Quantitative evaluation of demyelination presented as the demyelination score 624 
(DM) was performed on an average of 7 complete cross-sections of the spinal cord per mouse, as 625 
previously described by Storch et al. (Storch et al., 1998). All images were captured using a Leica 626 
Polyvar 2 microscope. 627 
For IF analyses, the paraffin-embedded spinal cord cross-sections were treated as previously 628 
described(82). After deparaffinization in xylol, sections were transferred to 90% (vol/vol) ethanol. 629 
Endogenous peroxidase was blocked by incubation in methanol with 0.02% H2O2 for 30 min at RT 630 
and rehydration to distilled water followed via a 90% (vol/vol), 70% (vol/vol), and 50% (vol/vol) 631 
ethanol series. Antigen retrieval was performed with Dako target retrieval solution (Dako) for 1 h 632 
in a steamer device at 98°C. Sections were subsequently incubated in 10% FCS in PBS for 30 min 633 
at RT before incubation with the primary antibody on 4°C, overnight. Primary antibodies used in 634 
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costainings were Mac3 (Rat, BD Biosciences, diluted 1:200), dMBP (Rabbit, Millipore diluted, 635 
1:200), CLEC7A (Rabbit, Abcam, diluted 1:500) and YFP (Chicken, Abcam, diluted 1:200), CD45 636 
(Rat, BD Biosciences, diluted 1:200), CLEC7A (Rabbit, Abcam diluted 1:200). After washing in 637 
PBS, sections were incubated with a secondary antibody for 1 h at RT. Secondary antibodies were 638 
used in the following combinations: Alexa Fluor 555 donkey anti-rat IgG (Abcam), Alexa Fluor 639 
488 donkey anti-rabbit IgG (Abcam) or rabbit anti-chicken IgY FITC (Thermo fischer), 640 
respectively. DAPI (0.2μg/ml) was included in the last washing step to visualize the nuclei.  All 641 
images were acquired using Zeiss LSM700 confocal microscope and the ZEN 2009 software. 642 
Representative images shown are maximum intensity projections of 3µm thick z-stacks. 643 
Quantifications of the specific immunoreactivity was performed on five whole spinal cord cross-644 
sections per mouse using ImageJ64, based on the number of pixels above an estimated threshold. 645 
 646 
Statistical Analysis 647 
GraphPad Prism 8 (http://www.graphpad.com/) was used for all the statistical analysis. In graphs 648 
with several comparisons, a dotted line separates the datasets that were compared. All figure 649 
legends include information regarding statistical tests used and sample size. 650 
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Supplementary materials 651 
Fig. S1. Recovery from experimental autoimmune encephalomyelitis (EAE) requires functional 652 
autophagy in the myeloid but not in the T cell compartment. 653 
Fig. S2. Atg7 and Ulk1 deficiency in microglia impact non-canonical and canonical autophagy, 654 
respectively.   655 
Fig. S3. Atg7 deficiency induces alterations in microglial transcriptome during experimental 656 
autoimmune encephalomyelitis (EAE). 657 
Fig. S4. Atg7 deficiency in microglia increases T cell proliferation and polarization to an 658 
inflammatory phenotype. 659 
Fig. S5. Gene-set enrichment analysis. 660 
Fig. S6. Atg7 deficient microglia have impaired scavenger receptor recirculation associated with 661 
increased inflammation and a reduced myelinating oligodendrocyte population in experimental 662 
autoimmune encephalomyelitis (EAE).  663 
Fig. S7. Late stage experimental autoimmune encephalomyelitis (EAE) is characterized by 664 
extensive tissue destruction and signs of increased in inflammation in mice with Atg7-deficient 665 
microglia. 666 
Fig. S8. Trehalose boosts experimental autoimmune encephalomyelitis (EAE) recovery and 667 
decreases immune infiltration in aged mice. 668 
Fig. S9. Gating strategy for defining cell populations by flow cytometry.  669 
 670 
Table S1. RNAseq data (Excel) 671 
Table S2. IPA, ORA and REVIGO analysis (Excel) 672 
Table S3. Genes shared among homeostatic or pathogenic gene sets (Excel) 673 
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Table S4. RNAseq data (Excel) 674 
Table S5. Technical data file (Excel) 675 
Table S6. Raw data (Excel) 676 
Movie S1. Accumulation of phagocytosed myelin in Atg7fl/fl Cx3cr1CreERT2 microglia 677 
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Fig. 1. Recovery from Experimental Autoimmune Encephalomyelitis (EAE) requires 898 
microglial autophagy.  899 
(A) Relative expression of Atg7 in microglia (CD45INT naïve; n = 4 and EAE;  n = 6), bone marrow-900 
derived monocytes/macrophages (CD45INT naïve; n = 3 and EAE; n = 3) and neutrophils (Ly6G+ 901 
naïve; n = 3 and EAE; n = 3) from naïve and day 15 EAE animals, detected by qPCR and 902 
normalized to the geometric mean of two endogenous control genes, Gapdh and Hprt. (B) Disease 903 
course in Atg7wt/wt (n = 16), Atg7wt/fl (n = 20) and Atg7fl/fl (n = 19) mice and (C) in Ulk1wt/wt (n = 904 
13), Ulk1fl/fl (n = 12) and Atg7fl/fl (n = 16) mice. Clinical course was compared using one-way 905 
ANOVA with Tukey’s post-hoc test on Area Under Curve. Error bars indicate confidence intervals. 906 
(D) Membrane bound LC3B (II) detected by flow cytometry in naïve Atg7wt/wt (untreated; n = 7, 907 
starved; n = 7), Ulk1fl/fl (untreated; n = 4, starved; n = 8), Atg7fl/fl (untreated; n = 4, starved; n = 8) 908 
and Atg7fl/f Ulk1fl/fl (“double knock-out”- DKO, untreated; n = 4, starved; n = 5)   microglia after 909 
starvation in vitro. (E) Relative expression of Rubicon in microglia (CD45INT naïve;  n = 6 and 910 
EAE, n = 4), bone marrow-derived monocytes/macrophages (CD45HI naïve; n = 4 and EAE; n = 911 
5) and neutrophils (Ly6G+ naïve; n = 6 and EAE; n = 5) from naïve and day 15 EAE animals, 912 
detected by qPCR and normalized to the geometric mean of two endogenous control genes, Gapdh 913 
and B-actin. (F) Phagocytosed myelin debris (dMBP) assessed in microglia from Atg7wt/wt, 914 
Ulk1fl/fl and Atg7fl/fl mice 21 days p.i. by flow cytometry (all conditions; n = 5). (G) Membrane 915 
bound LC3B (II) detected by flow cytometry after antibody labeling of ex vivo microglia 21 days 916 
p.i. in Atg7wt/wt (n = 5) and Atg7fl/fl (n = 6) mice. (H) Example images of immunofluorescence and 917 
image analysis of FluoromyelinTM stained myelin (FM Red), LC3B (II) and LC3B (II):Myelin 918 
(overlapping pixels) of ex vivo microglia 5 days p.i. from Atg7wt/wt (n = 4), Ulkfl/fl (n = 4) 919 
and  Atg7fl/fl (n = 6) mice. (I) In vitro pulsing of microglia 5 days p.i. with CellVueTM- and 920 
47 
 
pHrodoTM-stained myelin, assessed by flow cytometry (all conditions: n = 4 except “pHrodo” n = 921 
3).  (J) In vitro clearance of PKH26-stained myelin from medium by microglia 5 days p.i. from 922 
Atg7wt/wt (n = 7) and Atg7fl/fl (n = 7) mice. Statistics: (A, E and G) Mann-Whitney U-test, (D, F, H 923 
and J) Kruskal–Wallis test followed by Dunn's post-hoc test, (I) ANOVA followed by Dunnet's 924 
post-hoc test  (*** p < 0.001, ** p < 0.01, * p < 0.05). Error bars indicate SEM. Experiments (A 925 
to D and E, H) were performed twice and (B, C, F, G, I, J) three times.  926 
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  927 
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Fig. 2. Atg7 deficiency induces pronounced and sustained alterations in microglial 928 
transcriptome during Experimental Autoimmune Encephalomyelitis (EAE). 929 
Transcriptome analysis was performed using RNA-sequencing of microglia sorted from the 930 
following groups of mice: naive Atg7fl/fl (n = 4) and Atg7wt/wt (n = 3), day 21 p.i. Atg7fl/fl (n = 4, 931 
average score 3) and Atg7wt/wt (n = 3, average score 3) and day 35 p.i. Atg7fl/fl (n = 3, average score 932 
1.5) and Atg7wt/wt (n = 4, average score 2.5) (table S1). (A) Heat map depicting gene clusters 933 
associated with genotype and EAE disease stage based on transcripts that displayed a p-value < 934 
0.01 and fold-change > 1.5. The scale represents Z-score transformed expression values (with red 935 
and blue indicating upregulated and downregulated genes, respectively, compared to the mean 936 
value of a gene from all samples). These gene clusters were further grouped according to their 937 
pattern of expression into the four groups that were analyzed using Ingenuity pathway analysisTM 938 
(IPA) to annotate significance: (B) Canonical pathways, Upstream regulators, and Diseases and 939 
Functions (Benjamini-Hochberg adjusted p-value < 0.05) and (C) Over-representation analysis 940 
(ORA) for Diseases using the GLAD4U database (FDR < 0.05). Details regarding the differential 941 
expression analysis are presented in table S1 and a full list of significant functional annotations is 942 







Fig. 3. Atg7-deficient microglia have impaired myelin degradation and scavenger receptor 946 
recirculation associated to a pathogenic phenotype and increased inflammation in 947 
Experimental Autoimmune Encephalomyelitis (EAE).  948 
(A) Spinal cord microglia and infiltrating immune cell counts from Atg7wt/wt (n = 4) and Atg7fl/fl (n 949 
= 4) mice at day 21 p.i. analyzed by flow cytometry. (B) ELISA of supernatants from microglia 950 
sorted 21 days p.i. and incubated for 24h in vitro; Atg7wt/wt (n = 8) and Atg7fl/fl (n = 9). (C) 951 
Transcriptome of microglia sorted from Atg7wt/wt (n = 4) and Atg7fl/fl (n = 4) mice 35 days p.i. 952 
analyzed by RNA-sequencing and compared to microglia gene sets associated with disease and 953 
tissue homeostasis. (D) Representative images of immunofluorescence of CLEC7A and IBA1-954 
expressing microglia at day 32-37 p.i. in spinal cord from Atg7wt/wt and Atg7fl/fl mice. DAPI defines 955 
nuclei. Size bars correspond to 500µm and 50µm in the left and right panels, respectively. (E and 956 
F) Flow cytometry analysis of CLEC7A-expressing subpopulations in Atg7wt/wt (n = 6) and Atg7fl/fl 957 
(n = 6) microglia at day 35 p.i. (G) Flow cytometry analysis of the density of surface MSR1 staining 958 
in microglia from Atg7wt/wt (n = 6) and Atg7fl/fl (n = 6) mice in different subpopulations defined by 959 
levels of CLEC7A expression as shown in (E and F). (H) Uptake of labeled myelin by sorted 960 
Atg7wt/wt (control; n = 9, block; n = 8) and Atg7fl/fl (control; n = 6, block; n = 6) microglia after 961 
blocking of MSR1. (I) Flow cytometry quantification of intracellular MSR1 from naïve 962 
Atg7wt/wt  and Atg7fl/fl microglia exposed to myelin 12h in vitro w/wo 6h Bafilomycin A1 treatment.  963 
All conditions; n = 6. (J) Surface and intracellular MSR1 detection by flow cytometry in 964 
Atg7wt/wt (surface; n = 7, intracellular; n = 4) and Atg7fl/fl (surface; n = 7, intracellular; n = 5) 965 
microglia day 5 p.i. (K)  Expression of Apoe in Atg7wt/wt (n = 4),  Atg7fl/fl  (n = 5) and Bafilomycin 966 
A1 treated Atg7wt/wt  (n = 5) microglia exposed to myelin for 7 days in vitro. (L) ELISA of TGF-β1 967 
secretion from microglia from naïve and day 35 p.i. mice (Atg7wt/wt; n = 5, Ulkfl/fl; n = 5 and Atg7fl/fl; 968 
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n = 5) after 24h in vitro culture. (M) Intracellular myelin debris (dMBP) assessed in microglia from 969 
Atg7wt/wt (n = 12) and Atg7fl/fl (n = 12) mice 35 days p.i. by flow cytometry. (N)  Representative 970 
images of immunofluorescence of tissue deposits of myelin debris (dMBP) and density of Mac3+ 971 
macrophages at 37 p.i. in spinal cord from Atg7wt/wt and Atg7fl/fl mice. DAPI defines nuclei. 972 
Statistics: (A, B, F to H, J, L, M) Mann-Whitney U-test, (I and K) Kruskal–Wallis test followed 973 
by Dunn's post-hoc test (*** p < 0.001, ** p < 0.01, * p < 0.05). Error bars indicate SEM. 974 
Experiment (N) is representative of three independent experiments. Experiments (B, H to M) were 975 




Fig. 4. Trehalose treatment boosts myelin clearance and ameliorates Experimental 978 
Autoimmune Encephalomyelitis (EAE) in aged mice. 979 
(A) Transcriptome heat map of microglia sorted from naïve aged (> 80 weeks) wild type mice (n 980 
= 3, average score 2.5) and Atg7wt/wt (n = 4, average EAE score 1.5) and Atg7fl/fl (n = 4, average 981 
EAE score 2.5) mice 35 days p.i. analyzed by RNA-sequencing (table S4). The scale represents Z-982 
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score transformed expression values (with red and blue indicating upregulated and downregulated 983 
genes, respectively, compared to the mean value of a gene from all samples). (B)  Clinical course 984 
of EAE and full recovery rate in young (12-22 weeks old)  Atg7wt/wt (control; n = 11, treated; n = 985 
11), Ulk1fl/fl (control; n = 7, treated; n = 9) and Atg7fl/fl (control; n = 9, treated; n = 9 ) mice (left) 986 
and aged Atg7wt/wt (control; n = 4, treated; n = 6), Ulk1fl/fl (control; n = 4, treated; n = 5) and Atg7fl/fl 987 
(control; n = 5, treated; n = 5) mice (right). Mice were fed with Trehalose in water or water as 988 
control. Clinical course was compared using one-way ANOVA with Tukey’s post-hoc test on Area 989 
Under Curve. (C) Flow cytometry quantification of intracellular myelin debris in microglia from 990 
young (n = 3), aged (n = 4) and Trehalose-treated aged (n = 4) mice at day 21 p.i. (D) 991 
Immunofluorescence image and quantification showing TFEB translocation from cytosol to 992 
nucleus upon 48h in vitro Trehalose-treated (n = 14) and untreated (n = 8) microglia from aged 993 
mice at day 5 p.i. LAMP1 detects lysosomal structures. Data pooled from two experiments. (E) 994 
Expression of selected key autophagosome, lysosome and phagosome vesicle biogenesis genes in 995 
microglia of aged mice (n = 9) after 48h of ex vivo Trehalose treatment as fold change of untreated 996 
control. (F) In vitro myelin clearance assay of microglia sorted 5 days p.i. from young (n = 3), aged 997 
(n = 13) and Trehalose-treated young (n = 7) and aged (n = 5) mice pulsed 4 times with PKH26-998 
labeled myelin. (G) In vitro pulsing of microglia 5 days p.i. with CellVueTM- and pHrodoTM-stained 999 
myelin, assessed by flow cytometry (all conditions: n = 4 except aged 3h; n = 5). (H) CLEC7A 1000 
and APOE detected by Flow cytometry on ex vivo day 21 EAE microglia from Aged (n = 4) w/wo 1001 
Trehalose treatment (n = 4). (I) ELISA of cytokine production by CD11b+ cells isolated from the 1002 
CNS of young (n = 5), aged (n = 13) and Trehalose-treated aged (n = 10) mice at day 21 p.i. cultured 1003 
ex vivo for 24h. Statistics: (D, F to H) Mann-Whitney U-test, (C and I) Kruskal–Wallis test 1004 
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followed by Dunn's post-hoc test (*** p < 0.001, ** p < 0.01, * p < 0.05). Error bars indicate SEM. 1005 
Experiments (B to D and F to I) were performed twice.  1006 
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Fig. S1. Recovery from Experimental Autoimmune Encephalomyelitis (EAE) requires 1009 
functional autophagy in the myeloid but not in the T cell compartment.  1010 
(A) Myelin Oligodendrocyte Glycoprotein (MOG)-induced EAE in Atg7fl/flLckCre (n = 44), 1011 
Atg7fl/wtLckCre (n = 43) and Atg7wt/wtLckCre (n = 38) mice (three pooled experiments). (B) 1012 
Frequencies of cells from inguinal lymph nodes in Atg7fl/flLckCre (n = 3-5), Atg7fl/wtLckCre (n = 4-5), 1013 
and Atg7wt/wtLckCre (n = 5) mice as detected by flow cytometry. (C) MOG-induced EAE in 1014 
Atg7fl/flLyz2Cre (n = 15), Atg7fl/wtLyz2Cre (n = 10) and Atg7wt/wtLyz2Cre (n = 23) mice. (D) LysM 1015 
(Lyz2) expression was screened using a reporter system (Lyz2-Cre x Rosa26-STOP-YFP). Cells 1016 
from different tissues were extracted, stained with fluorescently labeled antibodies, acquired by 1017 
flow cytometry and analyzed by gating into different subsets according to the strategy defined 1018 
above in the graphs. YFP positivity is shown for control, heterozygous or homozygous animals in 1019 
representative plots, as well as frequencies of positive cells (shown as percent of each given 1020 
population) and mean fluorescence intensity (MFI) for YFP expression. Bone marrow neutrophils 1021 
and lung macrophages show near complete labelling, as expected. In microglia, 30-40% of cells in 1022 
the naïve state exhibit Lyz2 expression, while T and B cells show minimal targeting. (E) mRNA 1023 
expression of Atg7 loxP-flanked exon 14 normalized to Gapdh and -actin in microglia from 1024 
Atg7fl/flLyz2Cre (naïve; n = 3, day 15 p.i.; n = 3) and Atg7wt/wt Lyz2Cre controls (naïve; n = 3, day 15 1025 
p.i.; n = 3). (F) Membrane-bound LC3B (II) and (G) intracellular pHrodoTM-labeled myelin 1026 
detected in ex vivo day 30 p.i. microglia from Atg7fl/flLyz2Cre (n = 12) and Atg7wt/wt Lyz2Cre (n = 11) 1027 
mice by flow cytometry after 48h of myelin and LPS exposure in vitro. Statistics: (A and C) One-1028 
way ANOVA with Tukey’s post-hoc test on Area Under Curve. Error bars indicate confidence 1029 
interval; (B) Kruskal–Wallis test followed by Dunn's post-hoc test, (D, F to G) Mann-Whitney U-1030 
test, (E) Unpaired T-test (*** p < 0.001, ** p < 0.01, * p < 0.05). Error bars indicate SEM. 1031 
Experiments (A to C) were performed three times and (E to G) were performed twice. 1032 
58 
 
Supplementary Figure 2 1033 
 1034 
Fig. S2. Atg7 and Ulk1 deficiency in microglia impact non-canonical and canonical 1035 
autophagy, respectively.   1036 
(A) Scheme over the Tamoxifen inducible Cx3cr1CreERT2 gene deletion model. Cx3cr1CreERT2 is co-1037 
expressed with fluorescent eYFP. Expression of eYFP in infiltrating CD11b+CD45hi (monocytes), 1038 
CD11b+CD45hi/int Ly6G+ (neutrophils) and CD11bintCD45int (microglia) is shown in the flow 1039 
cytometry panels to the right. (B) mRNA expression of loxP-flanked Atg7 exon 14 normalized to 1040 
Gapdh and Hprt in microglia from Atg7fl/flCx3cr1CreERT2 (2 weeks; n =12, 42 weeks; n = 5) and 1041 
Atg7wt/wtCx3cr1CreERT2 (2 weeks; n =10, 42 weeks; n = 6) mice. (C) Flow cytometry detection of 1042 
ATG7 in microglia after in vitro (left) and in vivo (right) Tamoxifen-induced Atg7 deletion in 1043 
Atg7fl/flCx3cr1CreERT2 (n = 3) and Atg7wt/wt Cx3cr1CreERT2 (n = 4) mice. (D) IL-1β secretion by day 1044 
15 p.i. microglia from Atg7wt/wt Cx3cr1CreERT2 (n = 10), Ulk1fl/flCx3cr1CreERT2 (n = 5) and Atg7fl/fl 1045 
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Cx3cr1CreERT2 (n = 5) mice. (E) Mitochondrial membrane potential detected in in vitro LPS treated 1046 
and nutrient deprived Atg7wt/wt Cx3cr1CreERT2 (n = 4), Ulk1fl/flCx3cr1CreERT2 (n = 5) and Atg7fl/fl 1047 
Cx3cr1CreERT2 (n = 4) microglia. (F) Phagocytosis of pHrodoTM-labeled apoptotic cells by Atg7fl/fl-1048 
Cx3cr1CreERT2 (n = 4) and Atg7wt/wt Cx3cr1CreERT2 (n = 4) microglia quantified by flow cytometry.  1049 
Statistics: (B and F) Mann-Whitney U-test, (C) Unpaired T-test, (D and E) Kruskal–Wallis test 1050 
followed by Dunn's post-hoc test (*** p < 0.001, ** p < 0.01, * p < 0.05). Error bars indicate SEM. 1051 
Experiments (D and E) were performed twice.  1052 
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Supplementary Figure 3 1053 
 1054 
Fig. S3. Atg7 deficiency induces alterations in microglial transcriptome during Experimental 1055 
Autoimmune Encephalomyelitis (EAE). 1056 
Transcriptomic analysis was performed using RNA-sequencing of microglia sorted from naive 1057 
Atg7fl/fl Cx3cr1CreERT2 (n = 4) and Atg7wt/wt Cx3cr1CreERT2 (n = 3) mice, at 21 days p.i. from Atg7fl/fl 1058 
Cx3cr1CreERT2 (n = 4, average score 3) and Atg7wt/wt Cx3cr1CreERT2 (n = 3, average score 3) mice, 1059 
and at day 35 p.i. from Atg7fl/fl Cx3cr1CreERT2 (n = 3, average score 1.5) and Atg7wt/wt Cx3cr1CreERT2 1060 
(n = 4, average score 2.5) mice. REViGO visualization of Gene Ontology terms for Biological 1061 
Processes for four different patterns of changes: orange - represents changes, considerably more 1062 
pronounced in Atg7fl/fl Cx3cr1CreERT2 microglia that occurred early in disease (day 21 p.i.) and 1063 
returned to levels in the naïve state by day 35 p.i. (Fig. 2A); blue - represents genes that remained 1064 
downregulated during disease with Atg7fl/fl Cx3cr1CreERT2 microglia showing modest changes (Fig. 1065 
2A); yellow - had similar pattern to orange in wild type but Atg7fl/fl Cx3cr1CreERT2 microglia 1066 
demonstrated the opposite pattern (Fig. 2A); purple - represents genes that gradually increased their 1067 
expression during disease progression specifically in Atg7fl/fl Cx3cr1CreERT2 microglia (Fig. 2A). 1068 
Details regarding the differential expression analysis are presented in table S1 and a full list of 1069 






Supplementary Figure 4 1072 
 1073 
Fig. S4. Atg7 deficiency in microglia increases T cell proliferation and polarization to an 1074 
inflammatory phenotype. 1075 
(A) Cytokine secretion profile of CD3+ T cell infiltrating the spinal cord of mice day 21 p.i. Data 1076 
shows cell counts assessed by flow cytometry in Atg7wt/wtCx3cr1CreERT2 (n = 4) and 1077 
Atg7fl/flCx3cr1CreERT2 (n = 4) mice. (B) Flow cytometry detection of Ki67+ expression in T cells 1078 
sorted from mouse central nervous system day 21 p.i. and co-cultured in vitro with 1079 
Atg7wt/wtCx3cr1CreERT2 (n = 10) and Atg7fl/flCx3cr1CreERT2 (n = 6)  microglia for 36h. (C) Total 1080 
counts of CD4+ T cells after co-culture with Atg7wt/wtCx3cr1CreERT2 and Atg7fl/lCx3cr1CreERT2 1081 
microglia  as described in (B). (D) Cytokine secretion profile from CD4+ T cells in the setup 1082 
described in (B), as assessed by flow cytometry. Statistics: Mann-Whitney U-test for all 1083 
comparisons (***p < 0.001, **p < 0.01, *p < 0.05). Error bars indicate SEM. Experiments (A to 1084 




Supplementary Figure 5 1087 
 1088 
Fig. S5. Gene-set enrichment analysis.  1089 
Gene-set enrichment analysis of transcriptomes from sorted microglia at 21 days p.i. 1090 
Atg7fl/flCx3cr1CreERT2 (n = 4, average EAE score 3) and Atg7wt/wtCx3cr1CreERT2 (n = 3, average EAE 1091 
score 3) and at day 35 p.i. Atg7fl/flCx3cr1CreERT2 (n = 3, average EAE score 1.5), 1092 
Atg7wt/wtCx3cr1CreERT2 (n = 4, average EAE score 2.5) and aged Atg7wt/wtCx3cr1CreERT2 (n = 3, 1093 
average EAE score 2.5). Filled bars indicate significant enrichment (FDR q-value < 0.25) 1094 
Microglial reference gene sets from human and mouse models of central nervous system disease 1095 
64 
 
were extracted from publications as listed in the figure. Analysis was performed using whole gene 1096 
signatures and the most significant genes defined by publications. All gene sets and references can 1097 








Fig. S6. Atg7 deficient microglia have impaired scavenger receptor recirculation associated 1102 
with increased inflammation and a reduced myelinating oligodendrocyte population in 1103 
Experimental Autoimmune Encephalomyelitis (EAE).  1104 
(A) Flow cytometry quantification of surface CLEC7A and ITGAX (Cd11c) on 1105 
Atg7wt/wtCx3cr1CreERT2 (n = 5) and Atg7fl/flCx3cr1CreERT2 (n = 5) day 35 EAE microglia. (B) 1106 
IBA1+CLEC7A+ positive cells per mm2 in lesion area of central nervous system tissue day 32-37 1107 
after EAE induction of Atg7wt/wtCx3cr1CreERT2 (n = 5) and Atg7fl/flCx3cr1CreERT2 (n = 7). (C) Flow 1108 
cytometry assessment of surface CD200R, CD36 and IA/IE in Atg7wt/wtCx3cr1CreERT2 (n = 6) and 1109 
Atg7fl/flCx3cr1CreERT2 (n = 6) microglia populations defined by levels of CLEC7A expression as 1110 
defined in Fig. 3, E and F.  (D) Fold change increase of scavenger receptor mRNA expression in 1111 
Atg7fl/flCx3cr1CreERT2 (n = 4) compared to Atg7wt/wtCx3cr1CreERT2 (n = 3) microglia (RNA-1112 
sequencing, day 21 p.i., as in Fig. 2). Flow cytometry quantification of surface (E) MSR1 and (F) 1113 
CD36 on Atg7wt/wtCx3cr1CreERT2 (n = 6) and Atg7fl/flCx3cr1CreERT2 (n = 6) day 35 EAE microglia. 1114 
(G) Flow cytometry quantification of intracellular CD36 from naïve Atg7wt/wt and Atg7fl/fl 1115 
microglia exposed to myelin 12h in vitro w/wo 6h Bafilomycin A1 treatment.  All conditions; n = 1116 
6. (H) Flow cytometry quantification of surface and intracellular density of scavenger receptors 1117 
after 24h in vitro myelin exposure in Atg7wt/wtCx3cr1CreERT2 (n = 4) and Atg7fl/flCx3cr1CreERT2 (n = 1118 
4) microglia sorted at day 5 p.i. (I) Fold change increase of lipoprotein mRNA expression in 1119 
Atg7fl/flCx3cr1CreERT2 (n = 4) compared to Atg7wt/wtCx3cr1CreERT2 (n = 3) microglia (RNA-1120 
sequencing, day 21 p.i., as in Fig. 2). (J) Surface density of TREM2 assessed with flow cytometry 1121 
(n = 3 for all conditions). Statistics: Mann-Whitney U-test for all comparisons except (G) Kruskal–1122 
Wallis test followed by Dunn's post-hoc test and (J) Unpaired T-test (*** p < 0.001, ** p < 0.01, 1123 
* p < 0.05). Error bars indicate SEM. Experiments (A) were repeated three times and experiments 1124 




Supplementary Figure 7 1127 
 1128 
 1129 
Fig. S7. Late stage Experimental Autoimmune Encephalomyelitis (EAE) is characterized by 1130 




(A) Zoomed images and immunofluorescence quantification (as in Fig. 3N) of tissue deposits of 1133 
myelin debris (dMBP) and density of MAC3+ macrophages at day 32-40 p.i. in spinal cord from 1134 
Atg7wt/wtCx3cr1CreERT2 (dMBP, n = 5; MAC3, n = 10) and Atg7fl/flCx3cr1CreERT2 mice (dMBP, n = 1135 
7; MAC3, n = 10). DAPI defines nuclei. (B) Immunofluorescence depicting CD45+ cells and YFP+ 1136 
microglia in spinal cord from mice day 32-40 p.i. CD45+ pixel area quantified from three pooled 1137 
experiments (n = 10 per group). (C) Infiltrating immune cells and microglia from spinal cord of 1138 
Atg7wt/wtCx3cr1CreERT2 (n = 6) and Atg7fl/flCx3cr1CreERT2 (n = 9) mice at day 35 p.i. assessed by flow 1139 
cytometry. Counts indicate numbers of microglia and infiltrating immune cells (bone marrow 1140 
derived macrophages (BMDM), Ly6G+ neutrophils and CD3+ T-cells). (D) In vitro myelin 1141 
clearance assay of day 35 sorted central nervous system myeloid cells pulsed 3 times with PKH26 1142 
labeled myelin (Atg7wt/wtCx3cr1CreERT2; n = 10, Atg7fl/flCx3cr1CreERT2; n = 4). (E) Flow cytometry 1143 
detection of intracellular MOG in ex vivo stained microglia and BMDM at day 35 p.i. (n = 9 per 1144 
group). (F) Flow cytometry detection of cells from the oligodendrocyte lineage 30 days p.i. 1145 
Percentage of CD45-GALC+MOG+, reflecting a myelinating population, in Atg7fl/flCx3cr1CreERT2 1146 
(n = 5) and Atg7wt/wtCx3cr1CreERT2 (n = 5) mice. (G) Representative images of the spinal cord stained 1147 
with Luxol fast blue showing reduced myelination in the Atg7fl/flCx3cr1CreERT2 spinal cord during 1148 
days 27-40 p.i. Graph showing demyelination scores in Atg7fl/flCx3cr1CreERT2 (n = 6) compared to 1149 
Atg7wt/wtCx3cr1CreERT2 (n = 7) mice.  Statistics: Mann-Whitney U-test for all comparisons (*** p < 1150 
0.001, ** p < 0.01, * p < 0.05). Error bars indicate SEM. Experiments (D and E) were performed 1151 





Supplementary Figure 8 1155 
 1156 
Fig. S8. Trehalose boosts Experimental Autoimmune Encephalomyelitis (EAE) recovery and 1157 
decreases immune infiltration in aged mice.  1158 
(A) EAE recovery rate in young (12-22 weeks old),  Atg7wt/wtCx3cr1CreERT2 (control; n = 11, treated; 1159 
n = 11), Ulk1fl/flCx3cr1CreERT2 (control; n = 7, treated; n = 9) and Atg7fl/flCx3cr1CreERT2 (control; n 1160 
= 9, treated; n = 9 ) mice and aged Atg7wt/wtCx3cr1CreERT2 (control; n = 4, treated; n = 6), 1161 
Ulk1fl/flCx3cr1CreERT2 (control; n = 4, treated; n = 5) and Atg7fl/flCx3cr1CreERT2 (control; n = 5, 1162 
treated; n = 5) mice. Mice were treated with Trehalose or water control. (B) Infiltrating immune 1163 
cells and microglia from spinal cord of aged mice (n = 4) and Trehalose treated aged mice (n = 4) 1164 
at day 21 p.i. assessed by flow cytometry. Statistics: Mann-Whitney U-test for all comparisons (* 1165 
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 1172 
 1173 
  1174 
